IP Library › Granted Patent US 11,512,296
Granted Patent B2
US 11,512,296 · App. 17/171,017 · Granted Nov 29, 2022

Using proteases to control restriction enzyme activity

Inventors: Zhenyu Zhu (Lynnfield, MA); Dapeng Sun (Lexington, MA); Aine Quimby (Newburyport, MA); Michaela Shottes (Methuen, MA)
Assignee: ABclonal Science, Inc.
C12N9/22C12Q1/37
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,512,296
App. No.
17/171,017
Granted
Nov 29, 2022
Kind
B2
Abstract

Proteases are enzymes which hydrolyze protein enzymes, eliminating their activity. The present invention exploits the hydrolyzing activity of proteases including proteinase K, endoproteinase LysC and/or trypsin to control the activity of restriction enzymes and/or eliminate or reduce production of unwanted DNA or RNA fragments (known as star activity).

Claims (19)

1. A process of inhibiting or preventing star activity by NcoI or BamHI comprising:

digesting an oligomer using a reaction mixture including NcoI or BamHI, buffer and oligomer;

including in the reaction mixture or adding proteinase K, endoproteinase LysC and/or trypsin in order to inhibit or prevent star activity by NcoI or BamHI; and

terminating the digestion by adding a stopping solution including a loading dye.

2. The process of claim 1 wherein the oligomer is lambda DNA.

3. The process of claim 1 wherein the buffer is 20 mM Tris-HCl, pH 7.4, 40 mM KoAc, 10 mM MgCl 2 , 0.1 mM CaCl 2 ; or 20 mM Tris-HCl, pH 7.5, 40 mM NaCl, 10 mM MgCl 2 , 0.1 mM CaCl 2 .

4. The process of claim 1 wherein the stopping solution includes 2.5% Ficoll®-400, 11 mM EDTA (pH 8.0), 3.3 mM Tris-HCL, 0.017% SDS, 0.015% bromophenol blue.

5. The process of claim 4 wherein the stopping solution is added.

6. A process of determining the optimal relative concentrations to inhibit or prevent star activity by Ncol or BamHI, or Ncol or BamHI and a proteinase comprising:

(i) combining Ncol or BamHI, the proteinase, a buffer and an oligomer in order to achieve a starting concentration of each;

(ii) determining the star activity of Ncol or BamHI after a reaction time, and if there is any, diluting the reaction mixture and repeating the reaction for said reaction time;

(iii) repeating step (ii) until there is no star activity; and

(iv) determining the concentrations of Ncol or BamHI and proteinase at which star activity ceases.

7. The process of claim 6 wherein the proteinase are combined simultaneously with the restriction endonuclease.

8. The process of claim 6 wherein the proteinase is proteinase K, endoproteinase LysC or trypsin.

9. The process of claim 6 wherein the oligomer is lambda DNA.

10. The process of claim 6 wherein the buffer is: 20 mM Tris-HCl, pH 7.4, 40 mM KoAc, 10 mM MgCl2, 0.1 mM CaCl2; or 20 mM Tris-HCl, pH 7.5, 40 mM NaCl, 10 mM MgCl2, 0.1 mM CaCl2; and, 20 mM Tris-HCl, pH 8.0, 10 mM MgCl2, 0.1 mM CaCl2.

11. The process of claim 6 wherein Ncol or BamHI activity is terminated by addition of STOP solution.

12. The process of claim 1 wherein the buffer is 20 mM Tris-HCl, pH 8.0, 10 mM MgCl 2 , 0.1 mM CaCl 2 .

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 11, 2022
From: ZHU, ZHENYU; SUN, DAPENG; QUIMBY, AINE; SHOTTES, MICHAELA
To: ABCLONAL SCIENCE, INC.
Reel/Frame 059557/0477 →
Continuity (3)
Continuation 17062471 · Oct 2, 2020
Provisional Application 62916927 · Oct 18, 2019
Related Publication 20210171925A1 · Jun 10, 2021